ライフサイエンスコーパス: vesicular stomatitis virus

1 ve to the cytoplasmic replicating virus VSV (vesicular stomatitis virus).

2 ecting mice from neuropathogenesis caused by vesicular stomatitis virus.

3 ring infection by Listeria monocytogenes and vesicular stomatitis virus.

4 otection from death after CNS infection with vesicular stomatitis virus.

5 vels of RIG-I and resistance to infection by vesicular stomatitis virus.

6 the pseudotypes bearing the glycoprotein of vesicular stomatitis virus.

7 rovide an advantage for host defense against vesicular stomatitis virus.

8 n with lymphocytic choriomeningitis virus or vesicular stomatitis virus.

9 ligands but instead respond specifically to vesicular stomatitis virus.

10 is observed after intranasal challenge with vesicular stomatitis virus.

11 PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

12 a and IFN-beta, in protection from oncolytic vesicular stomatitis virus.

13 of H1N1, H6N2, and H11N9 IAV strains but not vesicular stomatitis virus.

14 In this article, we study the polymerase of vesicular stomatitis virus, a member of the rhabdoviruse

15 he RNA-dependent RNA polymerase L protein of vesicular stomatitis virus, a prototype of nonsegmented

16 pha-pretreated cells but that replication of vesicular stomatitis virus, a Rhabdovirus, and encephalo

17 Vesicular stomatitis virus, a single-stranded RNA virus,

18 nd challenged the animals with a recombinant vesicular stomatitis virus, a synthetic HCV genome, IFN

19 d vaccinia virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, a

20 Vesicular stomatitis virus and influenza A virus infecti

21 een after infection of IL-21R(-/-) mice with vesicular stomatitis virus and influenza virus.

22 n response to infection with the RNA viruses vesicular stomatitis virus and Sendai virus and to trans

23 constructs involving viral vectors (such as vesicular stomatitis virus), and antisense compounds dir

24 enveloped viruses (e.g., HIV, herpesviruses, vesicular stomatitis virus, and influenza virus).

25 ruses, including encephalomyocarditis virus, vesicular stomatitis virus, and influenza virus, in susc

26 ent viruses, such as oncolytic adenoviruses, vesicular stomatitis virus, and picornaviruses as well a

27 whereas other RNA viruses (Sindbis virus and vesicular stomatitis virus) are not.

28 gion I) of the L protein from a rhabdovirus, vesicular stomatitis virus, at 1.8-A resolution.

29 EBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expre

30 laque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expre

31 A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a su

32 observed in phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZE

33 ot-and-mouth disease virus, two serotypes of vesicular stomatitis virus, bluetongue virus, and bovine

34 by arboviruses, including Sindbis virus and vesicular stomatitis virus, but this innate restriction

35 d RNA virus, including influenza A virus and vesicular stomatitis virus, by a mechanism independent o

36 ved from viral infections with influenza and vesicular stomatitis virus can persist after resolution

37 al RNA-dependent RNA polymerase L protein of vesicular stomatitis virus catalyzes unconventional pre-

38 Using a recombinant vesicular stomatitis virus containing LUJV GP as its sol

39 We then explore a novel recombinant vesicular stomatitis virus (dG-VSV) with the G-gene dele

40 source antigens are expressed by vaccinia or vesicular stomatitis virus, either as proteasome-liberat

41 We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona v

42 mal human glia, fibroblasts, or melanocytes, vesicular stomatitis virus evoked robust beta interferon

43 th rVSVDeltaG*/BDVG, a cytolytic recombinant vesicular stomatitis virus expressing BDV G that mimics

44 in lungs following intranasal infection with vesicular stomatitis virus expressing OVA and influenza

45 ne of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprot

46 ression plasmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavir

47 these MAbs to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavir

48 remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses

49 pon infection of the Jurkat T-cell line with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudo

50 F) but, surprisingly, not the trafficking of vesicular stomatitis virus G protein (VSV-G) to the cell

51 T cells are resistant to both HIV R5 env and vesicular stomatitis virus G protein (VSV-G)-mediated fu

52 By contrast, secretory traffic of vesicular stomatitis virus G protein, recycling of inter

53 ination with virus-like particles displaying vesicular stomatitis virus G protein, RNAdjuvant promote

54 ola virus-like particles (VLPs) that express vesicular stomatitis virus G, wild-type EBOV GP (EBGP),

55 gradation of SAMHD1 does not rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors in

56 These trials used vesicular-stomatitis-virus-G protein (VSV-G)-LVs at high

57 hen an alphavirus RNA replicon expresses the vesicular stomatitis virus glycoprotein (VSV G) as the o

58 Forest virus RNA replicons that express the vesicular stomatitis virus glycoprotein (VSV G) has been

59 Vesicular stomatitis virus glycoprotein (VSV-G)-pseudoty

60 hy, we found that augmenting fusion with the vesicular stomatitis virus glycoprotein (VSVG) increased

61 rved with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycoprotein or with the amph

62 le-cycle RV complemented with a heterologous vesicular stomatitis virus glycoprotein.

63 uction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with m

64 stricted to retroviruses, as it also acts on vesicular stomatitis virus glycoproteins.

65 Vesicular stomatitis virus has been shown to bud basolat

66 measles virus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus

67 tent antiviral protection against Sendai and vesicular stomatitis virus in a TLR3 and type I IFN rece

68 In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vect

69 32gamma protected epithelial WISH cells from vesicular stomatitis virus-induced cell death.

70 wth inhibition, prolonged protection against vesicular stomatitis virus infection and enhanced transc

71 defect early after Listeria monocytogenes or vesicular stomatitis virus infection but comparable cyto

72 CD8(+) T cell differentiation during vesicular stomatitis virus infection differed significan

73 e switched Ig in response to immunization or vesicular stomatitis virus infection is strongly impaire

74 ce in lymphocytic choriomeningitis virus and vesicular stomatitis virus infection models.

75 Furthermore, SLEC differentiation during vesicular stomatitis virus infection was enhanced by adm

76 with apoptotic triggers such as etoposide or vesicular stomatitis virus infection, but disassemble in

77 osynthetic inhibition during influenza A and vesicular stomatitis virus infection, but not murine hep

78 Using an intranasal vesicular stomatitis virus infection, we demonstrated th

79 ation and to induce apoptosis in response to vesicular stomatitis virus infection.

80 xpression for EmGFP/IL-15 upregulation after vesicular stomatitis virus infection.

81 efractory to herpes simplex virus type 1 and vesicular stomatitis virus infection.

82 knockdown of tlr13 are highly susceptible to vesicular stomatitis virus infection.

83 Here, we define that vesicular stomatitis virus L initiates synthesis via a d

84 nfections with encephalomyocarditis virus or vesicular stomatitis virus led to higher levels of autop

85 ction as an entry inhibitor for JUNV and for vesicular stomatitis virus, lymphocytic choriomeningitis

86 inhibition also occurred in the presence of vesicular stomatitis virus M (matrix) protein, another v

87 mRNA export factors that are targeted by the vesicular stomatitis virus matrix protein to inhibit hos

88 tu formation of dsRNA in cells infected with vesicular stomatitis virus, measles virus, influenza A v

89 ADAM15 expression enhanced rhinovirus 16 and vesicular stomatitis virus-mediated proinflammatory cyto

90 es a rational approach to the attenuation of vesicular stomatitis virus neurovirulence.

91 action results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola

92 atic MAVS; challenge of transgenic mice with vesicular stomatitis virus or a synthetic HCV genome ind

93 of TRIM56 did not inhibit the replication of vesicular stomatitis virus or hepatitis C virus, a virus

94 s, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or murine leukemia virus Env

95 dary challenges with Listeria monocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispe

96 trovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2 Abs immune-

97 Among vaccines, only the vesicular stomatitis virus platform has been successful

98 iruses A and B, Newcastle disease virus, and vesicular stomatitis virus), positive-sense RNA viruses

99 and no impact on antibody neutralization of vesicular stomatitis virus pseudotyped with Ebola virus

100 on virus entry or coreceptor expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication

101 Using vesicular stomatitis virus pseudovirions bearing EBOV gl

102 ion conferred by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack nativ

103 sponses than UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, or adenovirus.

104 on with MV, p150 disruption had no effect on vesicular stomatitis virus, reovirus, or lymphocytic cho

105 esis and shows reduced capability to control vesicular stomatitis virus replication and to induce apo

106 study, we found Newcastle disease virus and vesicular stomatitis virus replication is enhanced in mo

107 by IFN in both glioma and melanoma, whereas vesicular stomatitis virus replication was blocked.

108 d-induced interferon production and enhanced vesicular stomatitis virus replication.

109 Adenovirus and vesicular stomatitis virus, representing viruses of the

110 ession of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homotypic virus-ce

111 proteins from La Crosse orthobunyavirus and vesicular stomatitis virus reveal insights into RNA synt

112 lescents and 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva.

113 Recently, we demonstrated that recombinant vesicular stomatitis virus (rVSV) expressing human NoV c

114 ough not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovir

115 Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing

116 development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a singl

117 onstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has sti

118 athology after immunization with recombinant vesicular stomatitis virus (rVSV) vaccine vectors, and i

119 Recombinant vesicular stomatitis virus (rVSV) was shown to be a high

120 icacy testing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccin

121 tenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidat

122 The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

123 approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

124 Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors,

125 With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea

126 In this study, we constructed a recombinant vesicular stomatitis virus (rVSV-VP1) expressing VP1, th

127 EBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surf

128 Reovirus and vesicular stomatitis virus single-cycle yields were comp

129 We have used a collection of vesicular stomatitis virus strains that had been evolvin

130 otype nonsegmented negative-sense RNA virus, vesicular stomatitis virus, suggest a role for P beyond

131 RS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glycoprotein G (VSV-G

132 cipitated HIV-1 gag particles containing the vesicular stomatitis virus type G envelope, HIV-1 envelo

133 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in L

134 otective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A

135 Remarkably, infection with vesicular stomatitis virus, vaccinia virus, and a variet

136 The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-Z

137 The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly

138 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancreatic duct

139 ed vaccine vectors based on live recombinant vesicular stomatitis virus (VSV) and a Semliki Forest vi

140 at intermediate pH for two vesiculoviruses, vesicular stomatitis virus (VSV) and Chandipura virus (C

141 Here we report that two other RNA viruses, vesicular stomatitis virus (VSV) and encephalomyocarditi

142 n of herpes simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV) and impaired the replic

143 f green fluorescent protein (GFP)-expressing vesicular stomatitis virus (VSV) and its oncolytically e

144 ve immune functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriom

145 influx was not detected after infection with vesicular stomatitis virus (VSV) and occurred only throu

146 The active template for RNA synthesis for vesicular stomatitis virus (VSV) and other negative-stra

147 nctional L protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catal

148 The glycoproteins (G proteins) of vesicular stomatitis virus (VSV) and related rhabdovirus

149 d infections with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncyti

150 that two RNA viruses with broad host ranges, vesicular stomatitis virus (VSV) and Sindbis virus (SINV

151 h available experimental data on the DMFE of Vesicular stomatitis virus (VSV) and Tobacco etch virus

152 Oncolytic viruses such as vesicular stomatitis virus (VSV) are being considered as

153 ers, which have been employed here to purify vesicular stomatitis virus (VSV) as a model case, howeve

154 y show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model virus on SP-

155 Using vesicular stomatitis virus (VSV) as a model, we coinfect

156 e, we describe such a strategy that utilizes vesicular stomatitis virus (VSV) as a vector for chimeri

157 re we demonstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) assemble to include CD4

158 Vesicular stomatitis virus (VSV) assembly requires conde

159 g ligands can be displayed on the surface of vesicular stomatitis virus (VSV) by engineering its glyc

160 Recombinant vesicular stomatitis virus (VSV) encoding the hemaggluti

161 VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F a

162 ion of ACT with systemic administration of a vesicular stomatitis virus (VSV) engineered to express t

163 Vesicular stomatitis virus (VSV) exhibits a remarkably r

164 ralizing antibody titers, measured against a vesicular stomatitis virus (VSV) expressing EBGP or Delt

165 Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zai

166 mental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire C

167 oped a bivalent recombinant vaccine based on vesicular stomatitis virus (VSV) expressing the Zaire eb

168 Here we describe the use of vesicular stomatitis virus (VSV) for tracing neuronal co

169 ecotropic Moloney murine leukemia virus and vesicular stomatitis virus (VSV) G glycoproteins; and (i

170 le retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G protein with dextran-

171 2, followed by two booster inoculations with vesicular stomatitis virus (VSV) G trans-complemented sc

172 y(C) binding protein 2 (PCBP2) downregulates vesicular stomatitis virus (VSV) gene expression.

173 ll interfering RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth.

174 Vesicular stomatitis virus (VSV) has been extensively st

175 Replication of vesicular stomatitis virus (VSV) has long served as a mo

176 ecause of its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a system

177 Vesicular stomatitis virus (VSV) has shown considerable

178 Vesicular stomatitis virus (VSV) has shown substantial p

179 ectious autonomously replicating recombinant vesicular stomatitis virus (VSV) in which the glycoprote

180 regions encompassing the appendage region of vesicular stomatitis virus (VSV) Indiana serotype L prot

181 tion of Gp78 results in a robust decrease of vesicular stomatitis virus (VSV) infection and a corresp

182 During vesicular stomatitis virus (VSV) infection, pDC depletio

183 vely regulating the host IFN response during vesicular stomatitis virus (VSV) infection.

184 lso known as IFP35) as a factor required for vesicular stomatitis virus (VSV) infection.

185 Vesicular stomatitis virus (VSV) is a bullet-shaped rhab

186 Vesicular stomatitis virus (VSV) is a highly cytopathic

187 Vesicular stomatitis virus (VSV) is a potential oncolyti

188 Vesicular stomatitis virus (VSV) is a promising oncolyti

189 Vesicular stomatitis virus (VSV) is a promising oncolyti

190 Vesicular stomatitis virus (VSV) is a promising oncolyti

191 Recombinant vesicular stomatitis virus (VSV) is a promising therapeu

192 Vesicular stomatitis virus (VSV) is a prototype nonsegme

193 Vesicular stomatitis virus (VSV) is a rhabdovirus that a

194 Vesicular stomatitis virus (VSV) is potent and a highly

195 Vesicular stomatitis virus (VSV) is the prototype for ne

196 electron cryomicroscopy the structure of the vesicular stomatitis virus (VSV) L protein.

197 plication-defective vaccine vectors based on vesicular stomatitis virus (VSV) lacking its envelope gl

198 The distribution of vesicular stomatitis virus (VSV) nucleocapsids in the cy

199 The vesicular stomatitis virus (VSV) nucleoprotein (N) assoc

200 vaccines containing antigens from influenza, vesicular stomatitis virus (VSV) or human immunodeficien

201 n direct cell-to-cell transmission of either vesicular stomatitis virus (VSV) or the retrovirus MoMLV

202 cellular proteins from cells expressing the vesicular stomatitis virus (VSV) P protein identified th

203 Assembly of vesicular stomatitis virus (VSV) particles requires the

204 Upon treatment with vesicular stomatitis virus (VSV) particles, plasmacytoid

205 diated degree of shielding and the amount of vesicular stomatitis virus (VSV) particles.

206 entry, 49 constructs were incorporated onto vesicular stomatitis virus (VSV) pseudoparticles and tra

207 A luciferase-expressing vesicular stomatitis virus (VSV) pseudotype that contain

208 adult flies; loss of Toll-7 led to increased vesicular stomatitis virus (VSV) replication and mortali

209 rticle RNA in HEK293 cells stably expressing vesicular stomatitis virus (VSV) replication proteins po

210 function by RNAi inhibited an early stage of vesicular stomatitis virus (VSV) replication.

211 The vesicular stomatitis virus (VSV) RNA-dependent RNA polym

212 stimulated genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable prom

213 s (MoMLV) spread, and only minimally affects vesicular stomatitis virus (VSV) spread, to adjacent cel

214 In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its n

215 study, we developed a recombinant strain of vesicular stomatitis virus (VSV) that specifically targe

216 By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore

217 with miRNA inhibitors in cells infected with vesicular stomatitis virus (VSV) to identify miRNAs that

218 zed the ability of a vaccine vector based on vesicular stomatitis virus (VSV) to induce a neutralizin

219 didate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that la

220 nfluenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and

221 Vesicular stomatitis virus (VSV) vectors that express he

222 rements in a simplified system, we generated vesicular stomatitis virus (VSV) virions pseudotyped wit

223 VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its

224 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of

225 ation method is demonstrated on an RNA-based vesicular stomatitis virus (VSV) with oncolytic properti

226 Vesicular stomatitis virus (VSV), a negative-sense RNA v

227 Vesicular stomatitis virus (VSV), a negative-strand RNA

228 l proteins potently inhibit the infection of vesicular stomatitis virus (VSV), a prototype member of

229 Working with vesicular stomatitis virus (VSV), a prototype of NNS RNA

230 Vesicular stomatitis virus (VSV), a prototype of the Rha

231 Work with vesicular stomatitis virus (VSV), a prototype, supports

232 Using vesicular stomatitis virus (VSV), a prototypic NS RNA vi

233 Here we show, using vesicular stomatitis virus (VSV), a relative of rabies v

234 aviviridae, but has no appreciable effect on vesicular stomatitis virus (VSV), a rhabdovirus.

235 We injected vesicular stomatitis virus (VSV), a transsynaptic tracer

236 K-deficient MEFs exhibit impaired control of vesicular stomatitis virus (VSV), a virus sensed by STIN

237 ruses, encephalomyocarditis virus (EMCV) and vesicular stomatitis virus (VSV), activate the NLRP3 inf

238 ly used to pseudotype glycoprotein-deficient vesicular stomatitis virus (VSV), allowing studies of BA

239 this observation, we engineered a strain of vesicular stomatitis virus (VSV), an oncolytic rhabdovir

240 activity of these ISGs against an RNA virus, vesicular stomatitis virus (VSV), and a DNA virus, murin

241 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothe

242 xpressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with establ

243 ombinant rabies virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the

244 binant rhabdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type o

245 ced the replication of a heterologous virus, vesicular stomatitis virus (VSV), in a SOCS1-dependent m

246 RNA of negative-strand RNA viruses, such as vesicular stomatitis virus (VSV), is completely enwrappe

247 The virus studied here, vesicular stomatitis virus (VSV), like its relative, rab

248 d whether a rapidly replicating rhabdovirus, vesicular stomatitis virus (VSV), requires the PI3k/Akt

249 al infection with influenza A virus (IAV) or vesicular stomatitis virus (VSV), respectively.

250 Theiler's murine encephalitis virus (TMEV), vesicular stomatitis virus (VSV), Sindbis virus, Newcast

251 ted DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to protect it from nAb

252 Here, a prototype RNA virus, vesicular stomatitis virus (VSV), was cultured for three

253 RdRP with those of the related rhabdovirus, vesicular stomatitis virus (VSV), we demonstrate that bo

254 cell lines and primary fibroblasts with the vesicular stomatitis virus (VSV), we detected DNA comple

255 By studying vesicular stomatitis virus (VSV), we identify the large

256 Working with vesicular stomatitis virus (VSV), we previously showed t

257 reporter strain of the negative-sense ssRNA vesicular stomatitis virus (VSV), we show that microinje

258 pplication of a novel viral tracer, based on vesicular stomatitis virus (VSV), which directs retrogra

259 We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expre

260 Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses

261 In this study, we developed a vesicular stomatitis virus (VSV)-based human NoV vaccine

262 Using a vesicular stomatitis virus (VSV)-based pseudoparticle se

263 Here, vesicular stomatitis virus (VSV)-based pseudovirions dis

264 We produced a recombinant vesicular stomatitis virus (VSV)-based vaccine vector ex

265 antibody repertoire after administration of vesicular stomatitis virus (VSV)-Ebola vaccine at 3 mill

266 One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVS

267 not contain the larger cargoes, collagen or Vesicular stomatitis virus (VSV)-G glycoprotein.

268 a neutralization titer of > or =1:20 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 3

269 In the vesicular stomatitis virus (VSV)-induced encephalitis mo

270 -like helicase (RLH) signaling contribute to vesicular stomatitis virus (VSV)-mediated triggering of

271 ue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon beta

272 We developed a recombinant vesicular stomatitis virus (VSV)-SRV vaccine consisting

273 t cell targets for the matrix (M) protein of vesicular stomatitis virus (VSV).

274 NS RNA viruses comes largely from studies of vesicular stomatitis virus (VSV).

275 r pattern was observed for the IFN-sensitive vesicular stomatitis virus (VSV).

276 al infection by the neurotropic rhabdovirus, vesicular stomatitis virus (VSV).

277 and it inhibits the replication of HSV-1 and vesicular stomatitis virus (VSV).

278 cytopathic viruses, such as the neurotropic vesicular stomatitis virus (VSV).

279 domain of the unrelated glycoprotein (G) of vesicular stomatitis virus (VSV).

280 ensor and effector responses to intratumoral vesicular stomatitis virus (VSV).

281 ve and cells that are resistant to oncolytic vesicular stomatitis virus (VSV).

282 h influenza virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV).

283 ll carcinoma (HNSCC) lines from oncolysis by vesicular stomatitis virus (VSV).

284 mouse model of prostate cancer infected with vesicular stomatitis virus (VSV).

285 results suggested a higher neutralization of vesicular stomatitis virus (VSV)/HCV E1-G pseudotype inf

286 ite-directed mutagenesis of the L protein of vesicular stomatitis virus (VSV, a prototypic NNS RNA vi

287 A recombinant vesicular stomatitis virus (VSV-PeGFP-M-MmRFP) encoding

288 hanisms by which the transmembrane domain of vesicular stomatitis virus (VSV-TMD) promotes both initi

289 Recombinant vesicular stomatitis viruses (VSV) are excellent candida

290 Here we test replication-competent vesicular stomatitis viruses (VSV) on 19 primary human m

291 Here we show that both RNA (vesicular stomatitis virus [VSV]) and DNA (cytomegalovir

292 se in early endosomes (SFV, SINV, CHIKV, and vesicular stomatitis virus [VSV]), while viruses that fu

293 eins via replication incompetent recombinant vesicular stomatitis viruses (VSVs) and human adenovirus

294 Vesicular stomatitis viruses (VSVs) containing wild-type

295 We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatme

296 cell lines to infection by the nonretrovirus vesicular stomatitis virus were indistinguishable.

297 sed by two TLR3-dependent viruses (HSV-1 and vesicular stomatitis virus) were high in fibroblasts fro

298 starting with poliovirus and then moving to vesicular stomatitis virus, where he discovered a virion

299 2503202) evaluated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

300 safety and immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl